Advances in Osteoarthritis pp 153-162 | Cite as
Results of a Phase II Rheumatoid Arthritis Clinical Trial Using T-Cell Receptor Peptides
Summary
Restricted T-cell receptor gene use has been found in animal models of autoimmune disease. This observation has resulted in the successful use of T-cell receptor peptide therapy in animal studies. Initial phase I studies in patients with rheumatoid arthritis (RA) indicated that this therapy was safe and well tolerated. A double-blind, placebo-controlled, multicenter phase II rheumatoid arthritis clinical trial was undertaken using IR501 therapeutic vaccine, which consists of a combination of three peptides derived from T-cell receptors (Vβ3, Vβ14, Vβ17) in incomplete Freund’s adjuvant (IFA). These T-cell receptors were previously reported to be restricted in RA patients. A total of 99 patients received either 90μg (31 patients) or 300μg (35 patients) of IR501 therapeutic vaccine or IFA alone (33 patients) as a control. IR501 therapeutic vaccine was administered as a 1.0-ml intramuscular injection at weeks 0, 4, 8, and 20. Patients were followed for 32 weeks. The results of the trial indicated that the treatment was safe, with none of the patients discontinuing the trial because of treatment-related adverse events. No significant adverse events attributable to the study drug were observed. Patients in both dose groups treated with IR501 therapeutic vaccine showed improvement in disease condition. Most importantly, the 90-μg dose group showed a statistically significant improvement when compared to control patients after the third and fourth injections. More than 50% of the treated patients showed improvement compared to 19% of controls, as measured in accordance with the American College of Rheumatology definition for clinical response (ACR 20 criteria).
Key Words
T-cell receptor peptide vaccine Phase II rheumatoid arthritis trial Vβ3 Vβ14 Vβ17 T-cell receptors Rheumatoid arthritisPreview
Unable to display preview. Download preview PDF.
References
- 1.Ben-Nun A, Wekerle H, Cohen IR, et al (1981) Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature (Lond) 292:60–61CrossRefGoogle Scholar
- 2.Acha-Orbea H, Mitchell DJ, Timmermann L, et al (1988) Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54:263–273PubMedCrossRefGoogle Scholar
- 3.Urban JL, Kumar V, Kono DH, et al (1988) Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilites for antibody therapy. Cell 54:577–592PubMedCrossRefGoogle Scholar
- 4.Burns FR, Li X, Shen N, et al (1989) Both rat and mouse T cell receptors specific for the encephalitogenic determinants of myelin basic protein use similar Va or Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 169:27–39PubMedCrossRefGoogle Scholar
- 5.Chluba J, Steeg C, Becker A, et al (1989) T cell receptor β chain usage in myelin basic protein-specific rat T lymphocytes. Eur J Immunol 19:279–284PubMedCrossRefGoogle Scholar
- 6.Howell MD, Winters ST, Olee T, et al (1989) Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246:668–670PubMedCrossRefGoogle Scholar
- 7.Brostoff SW (1993) Vaccination with T-cell receptor peptides. In: Bach J-F (ed) Monoclonal antibodies and peptide therapy in autoimmune diseases. Dekker, New York, pp 203–218Google Scholar
- 8.Vandenbark AA, Hashim G, Offner H (1989) Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature (Lond) 341:541–544CrossRefGoogle Scholar
- 9.Offner H, Hashim GA, Vandenbark AA (1991) T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251:430–432PubMedCrossRefGoogle Scholar
- 10.Sedgwick J, Brostoff S, Mason D (1987) Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. J Exp Med 165:1058–1075PubMedCrossRefGoogle Scholar
- 11.Howell MD, Dively JP, Lundeen KA, et al (1991) Limited T cell receptor β-chain heterogeneity among IL-2R+ synovial T cells suggests a role for superantigen in rheumatoid arthritis. Proc Natl Acad Sci USA 88:10921–10925PubMedCrossRefGoogle Scholar
- 12.Alam A, Lulé J, Coppin H, et al (1995) T-cell receptor variable region of the β -chain gene use in peripheral blood and multiple synovial membranes during rheumatoid arthritis. Hum Immunol 42:331–339PubMedCrossRefGoogle Scholar
- 13.Williams WV, Kieber-Emmons T, Fang Q, et al (1993) Conserved motifs in rheumatoid arthritis synovial tissue T-cell receptor β chains. DNA Cell Biol 12:425–434PubMedCrossRefGoogle Scholar
- 14.Zagon G, Tumang JR, Li Y, et al (1994) Increased frequency of V/317-positive T cells in patients with rheumatoid arthritis. Arthritis Rheum 37:1431–1440PubMedCrossRefGoogle Scholar
- 15.Kim SY, Lee EY, Kim YI, et al (1995). T cell receptor Vβ gene usage in rheumatoid arthritis of Korean patients. FASEB J 9:A525Google Scholar
- 16.Goronzy JJ, Bartz-Bazzanella P, Hu W, et al (1994) Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis. J Clin Invest 94:2068–2076PubMedCrossRefGoogle Scholar
- 17.Grom AA, Thompson SD, Luyrink L, et al (1993) Dominant T-cell-receptor β chain variable region V/?14+ clones in juvenile rheumatoid arthritis. Proc Natl Acad Sci USA 90:11104–11108PubMedCrossRefGoogle Scholar
- 18.Paliard X, West SG, Lafferty JA, et al (1991) Evidence for the effects of a superantigen in rheumatoid arthritis. Science 253:325–329PubMedCrossRefGoogle Scholar
- 19.Moreland L.W, Heck L.W Jr, Koopman W.J, et al (1996) Vβ 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 23:1353–1362PubMedGoogle Scholar